ngs: changes in cll management
Published 4 years ago • 107 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
2:01
the evolution of bcl2 inhibition in cll
-
0:53
all-cll: an ngs panel for molecular characterization of cll
-
1:29
the importance of treatment sequencing in cll
-
1:23
next-generation sequencing in cll
-
1:30
exciting new agents in cll
-
12:46
fixed duration treatment strategies in cll
-
2:26
outcomes of ven-based regimens in cll/sll following intolerance or progression on covalent btki's
-
4:02
testing for bcr::abl kinase mutations in cml and how they impact tki resistance
-
2:11
mutational profiling: ngs and molecular assays
-
1:04
overcoming the limits to widespread ngs implementation
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
1:12
the reduced prognostic impact of the cll-ipi in the new era of targeted agents
-
2:29
new trends in the management of leukemia
-
3:29
how the management of cll is evolving
-
1:42
the future of cll treatment: aiming for long-lasting remission
-
0:53
the future of cll treatment
-
2:08
the differences in outcomes and treatment in cll patients with mutated and unmutated ighv
-
0:57
how reliable is ngs in diagnosing aml?
-
2:48
comparability of next generation gene panel assays in cll
-
0:45
key trials in cll and designing a concept for treatment
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
1:37
ngs can detect low level kd mutations in cp-cml patients